Dmitry Balyasny’s Olema Pharmaceuticals OLMA Stock Holding History

Dmitry Balyasny’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-89,671	Closed	-$1.34M	–	3371
2026 Q1	$1.34M	Sell	89,671 -77,637	-46%	-$1.73M	﹤0.01%	1954
2025 Q4	$4.18M	Sell	167,308 -525,871	-76%	-$9.36M	0.01%	1493
2025 Q3	$6.79M	Buy	+693,179	New	+$4.16M	0.01%	1236
2025 Q2	–	Sell	-113,018	Closed	-$425K	–	3205
2025 Q1	$425K	Sell	113,018 -1,014,571	-90%	-$5.1M	﹤0.01%	2335
2024 Q4	$6.57M	Buy	1,127,589 +418,492	+59%	+$4.18M	0.01%	1140
2024 Q3	$8.47M	Buy	+709,097	New	+$9.07M	0.01%	1034
2022 Q4	–	Sell	-12,097	Closed	-$33K	–	3096
2022 Q3	$33K	Buy	+12,097	New	+$51.3K	﹤0.01%	2522

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Dmitry Balyasny's OLMA Position: Q2 2026 in Review

Dmitry Balyasny sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 89,671 shares — an estimated $1.34M sold.

Dmitry Balyasny first reported a position in OLMA in Q3 2022 and held it in 7 quarters. The position peaked at $8.47M in Q3 2024. 182 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

Dmitry Balyasny reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 89,671 Olema Pharmaceuticals shares in Q2 2026, an estimated $1.34M.
Dmitry Balyasny first reported a position in Olema Pharmaceuticals in Q3 2022 and held it in 7 quarters.
Dmitry Balyasny's Olema Pharmaceuticals position peaked at $8.47M in Q3 2024.
182 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.